ACTOS SUMMARY
ACTOS (pioglitazone hydrochloride) is an oral antidiabetic agent that acts primarily by decreasing insulin resistance. ACTOS is used in the management of type 2 diabetes mellitus (also known as non-insulin-dependent diabetes mellitus [NIDDM] or adult-onset diabetes). Pharmacological studies indicate that ACTOS improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis. ACTOS improves glycemic control while reducing circulating insulin levels.
ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes (non-insulin-dependent diabetes mellitus, NIDDM). ACTOS is indicated for monotherapy. ACTOS is also indicated for use in combination with a sulfonylurea, metformin, or insulin when diet and exercise plus the single agent does not result in adequate glycemic control.
Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise. These efforts are important not only in the primary treatment of type 2 diabetes, but also to maintain the efficacy of drug therapy.
|
ACTOS NEWS HIGHLIGHTS Media Articles Related to Actos (Pioglitazone)
Health Tip: Finding Hidden Lactose
Source: MedicineNet Lactose Intolerance Specialty [2009.04.15]
Title: Health Tip: Finding Hidden Lactose
Category: Health News
Created: 4/15/2009 2:00:00 AM
Last Editorial Review: 4/15/2009
Lactose Tolerance Test
Source: MedicineNet Dyspepsia Specialty [2009.04.03]
Title: Lactose Tolerance Test
Category: Procedures and Tests
Created: 11/27/1998 5:08:00 PM
Last Editorial Review: 4/3/2009
Lactose Intolerance
Source: MedicineNet Hydrogen Breath Test Specialty [2008.05.08]
Title: Lactose Intolerance
Category: Diseases and Conditions
Created: 12/14/1998 7:21:00 PM
Last Editorial Review: 5/8/2008
More Broken Bones With Actos, Avandia
Source: MedicineNet pioglitazone Specialty [2008.04.29]
Title: More Broken Bones With Actos, Avandia
Category: Health News
Created: 4/29/2008
Last Editorial Review: 4/29/2008
ACTOS shows significant benefits for diabetics
Source: The Doctors Lounge - Endocrinology and Diabetes
A study shows that ACTOS reduces the risk of cardiovascular events by an extra 16% on top of standard medication.
Published Studies Related to Actos (Pioglitazone)
Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. [2009.02]
Context: Polycystic ovary syndrome (PCOS) is characterized by insulin resistance, compensatory hyperinsulinemia, increased prevalence of impaired glucose tolerance, and increased ovarian androgen biosynthesis. Objective: The aim of the study was to evaluate effects of pioglitazone [generic for Actos] on whole body insulin action and ovarian androgen biosynthesis in PCOS...
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. [2009.01]
BACKGROUND: Non-alcoholic steatohepatitis (NASH) is a common liver disease associated with obesity and diabetes.This protocol was approved by all participating center Institutional Review Boards (IRBs) and an independent Data and Safety Monitoring Board (DSMB) which was established for monitoring the accumulated interim data as the trial progresses to ensure patient safety and to review efficacy as well as the quality of data collection and overall study management.
Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes: what to add--insulin glargine or pioglitazone? [2008.12]
BACKGROUND: While metformin is the first line treatment in type 2 diabetes, the best way to escalate therapy is not always clear, particularly whether to add one or two oral agents or to introduce insulin... CONCLUSIONS: The results demonstrate characteristic differences in the effects of insulin glargine vs. pioglitazone [generic for Actos] on measures of beta-cell function and insulin sensitivity as well as cardiac load.
Pioglitazone inhibits the expression of inflammatory cytokines from both monocytes and lymphocytes in patients with impaired glucose tolerance. [2008.12]
CONCLUSIONS: These results demonstrate that PIO therapy in IGT can reduce proinflammatory gene and protein expression from both monocytes and lymphocytes. This intervention also reduces the inflammatory cross-talk between these immune cells and adipose tissue, which could in turn contribute to the metabolic improvements resulting from PIO therapy.
Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk. [2008.11]
We investigated the effect of atorvastatin monotherapy and combined treatment with atorvastatin and pioglitazone [generic for Actos] on intima-media thickness, vascular function and the cardiovascular risk profile. In all, 148 patients (76 male, 72 female; aged 61.4+/-6.5 years; body mass index [BMI] 29.2+/-4.1 kg/m2; mean +/- SD) with increased cardiovascular (CV) risk factors were randomised...
Clinical Trials Related to Actos (Pioglitazone)
A Portion-Controlled Diet Will Prevent Weight Gain in Diabetics Treated With ACTOS [Active, not recruiting]
We hypothesized that a portion controlled diet would prevent the weight gain associated with
the use of a peroxisome profliferator-activated receptor-gamma (PPAR-g). This is a 4 months
randomized clinical trial in type 2 diabetics who are treated with pioglitazone and a
standard diet, pioglitazone and a portion-controlled diet and metformin with a standard
diet.
Fasting Study of Pioglitazone HCl Tablets 45 mg and Actos® Tablets 45 mg [Completed]
The objective of this study was to investigate the bioequivalence of Mylan pioglitazone HCl
45 mg tablets to Takeda Actos® 45 mg tablets following a single, oral 45 mg (1 x 45 mg) dose
administration under fasting conditions.
Food Study of Pioglitazone HCl Tablets 45 mg to Actos® Tablets 45 mg [Completed]
The objective of this study was to investigate the bioequivalence of Mylan pioglitazone HCl
45 mg tablets to Takeda Actos® 45 mg tablets following a single, oral 45 mg (1 x 45 mg) dose
administration under fed conditions.
A Study to Evaluate SYR-322 Plus Pioglitazone HCl (Actos®), SYR-322 Alone, or Pioglitazone HCl Alone for the Treatment of Type 2 Diabetes [Active, not recruiting]
This is a randomized, double-blind, placebo-controlled study to evaluate the efficacy and
safety of SYR-322 plus pioglitazone HCl, SYR-322 alone, or pioglitazone alone in subjects
with type 2 diabetes.
Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation (PERISCOPE) [Completed]
|
